Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review
Catarina Domingues, Maria Ferreira, Rosa Pinho · 2026
Read Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review by Catarina Domingues, Maria Ferreira, Rosa Pinho (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13322461.txt.
Description
Catarina Domingues, Maria Ferreira and Rosa Pinho review, in 2026, weight and metabolic drugs for people with severe mental illness. Antipsychotic medicines often cause weight gain, insulin resistance and abnormal lipids, driving early death from heart and metabolic disease. Monitoring alone has not solved the problem.
Their structured search covered trials and syntheses from 2015 to 2025, yielding nine studies of GLP-1 receptor agonists, the drug class widely used for diabetes and obesity. Liraglutide and semaglutide reliably reduced weight and improved blood sugar control, with no sign of worsening psychiatric symptoms. Exenatide showed no extra weight loss over placebo. Gut side effects were the commonest problems and were usually mild to moderate. Small samples and short follow-up limit certainty, the authors caution.
Catalog record
| CREATOR | Catarina Domingues, Maria Ferreira, Rosa Pinho |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |